Robin Michelet1,2, Lien Dossche3,4, Charlotte Van Herzeele3,5, Pauline De Bruyne3,4, Elke Gasthuys3,6, Jan Van Bocxlaer1, Johan Vande Walle3,4, An Vermeulen7. 1. Laboratory of Medical Biochemistry and Clinical Analysis, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium. 2. Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany. 3. Department of Paediatric Nephrology, Ghent University Hospital, Ghent, Belgium. 4. Department of Internal Medicine and Paediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium. 5. Department of Clinical Psychology, General Hospital Sint-Jan Bruges-Ostend, Brugge, Belgium. 6. Department of Pharmacology, Toxicology and Biochemistry, Faculty of Veterinary Medicine, Ghent University, Ghent, Belgium. 7. Laboratory of Medical Biochemistry and Clinical Analysis, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium. AnMC.Vermeulen@UGent.be.
Abstract
INTRODUCTION: The bioequivalence of two formulations of desmopressin (dDAVP), a vasopressin analogue prescribed for nocturnal enuresis treatment in children, has been previously confirmed in adults but not in children. In this study, we aimed to study the pharmacokinetics (PK) and pharmacodynamics (PD) of these two formulations, in both fasted and fed children, including patients younger than 6 years of age. METHODS: Previously published data from one PK study and one PK/PD study in children aged between 6 and 16 years were combined with a new PK/PD study in children aged between 6 months and 8 years, and analysed using population PK/PD modelling. Simulations were performed to further explore the relative bioavailability of both formulations and evaluate current dosing strategies. RESULTS: The complex absorption behaviour of the lyophilizate was modelled using a double input, linked to a one-compartmental model with linear elimination and an indirect response model linking dDAVP concentration to produced urine volume and osmolality. The final model described the observed data well and elucidated the complexity of bioequivalence and therapeutic equivalence of the two formulations. Simulations showed that current dosing regimens using a fixed dose of lyophilizate 120 μg is not adequate for children, assuming children to be in the fed state when taking dDAVP. A new age- and weight-based dosing regimen was suggested and was shown to lead to improved, better tailored effects. CONCLUSIONS: Bioequivalence and therapeutic equivalence data of two formulations of the same drug in adults cannot be readily extrapolated to children. This study shows the importance of well-designed paediatric clinical trials and how they can be analysed using mixed-effects modelling to make clinically relevant inferences. A follow-up clinical trial testing the proposed dDAVP dosing regimen should be performed. CLINICAL TRIAL REGISTRATION: This trial has been registered at www.clinicaltrials.gov (identifier NCT02584231; EudraCT 2014-005200-13).
RCT Entities:
INTRODUCTION: The bioequivalence of two formulations of desmopressin (dDAVP), a vasopressin analogue prescribed for nocturnal enuresis treatment in children, has been previously confirmed in adults but not in children. In this study, we aimed to study the pharmacokinetics (PK) and pharmacodynamics (PD) of these two formulations, in both fasted and fed children, including patients younger than 6 years of age. METHODS: Previously published data from one PK study and one PK/PD study in children aged between 6 and 16 years were combined with a new PK/PD study in children aged between 6 months and 8 years, and analysed using population PK/PD modelling. Simulations were performed to further explore the relative bioavailability of both formulations and evaluate current dosing strategies. RESULTS: The complex absorption behaviour of the lyophilizate was modelled using a double input, linked to a one-compartmental model with linear elimination and an indirect response model linking dDAVP concentration to produced urine volume and osmolality. The final model described the observed data well and elucidated the complexity of bioequivalence and therapeutic equivalence of the two formulations. Simulations showed that current dosing regimens using a fixed dose of lyophilizate 120 μg is not adequate for children, assuming children to be in the fed state when taking dDAVP. A new age- and weight-based dosing regimen was suggested and was shown to lead to improved, better tailored effects. CONCLUSIONS: Bioequivalence and therapeutic equivalence data of two formulations of the same drug in adults cannot be readily extrapolated to children. This study shows the importance of well-designed paediatric clinical trials and how they can be analysed using mixed-effects modelling to make clinically relevant inferences. A follow-up clinical trial testing the proposed dDAVP dosing regimen should be performed. CLINICAL TRIAL REGISTRATION: This trial has been registered at www.clinicaltrials.gov (identifier NCT02584231; EudraCT 2014-005200-13).
Authors: Stefan T Kaehler; Ilka M Steiner; Robert Sauermann; Helmut Scheidl; Markus Mueller; Christian Joukhadar Journal: Pharmacology Date: 2006-04-10 Impact factor: 2.547
Authors: Pauline De Bruyne; Ann De Guchtenaere; Charlotte Van Herzeele; Ann Raes; Jo Dehoorne; Piet Hoebeke; Erik Van Laecke; Johan Vande Walle Journal: Eur J Pediatr Date: 2013-08-30 Impact factor: 3.183
Authors: Johan G J Vande Walle; Guy A Bogaert; Sven Mattsson; Thierry Schurmans; Piet Hoebeke; Veerle Deboe; Jens Peter Norgaard Journal: BJU Int Date: 2006-03 Impact factor: 5.588
Authors: Elke Gasthuys; An Vermeulen; Siska Croubels; Joske Millecam; Stijn Schauvliege; Thomas van Bergen; Pauline De Bruyne; Johan Vande Walle; Mathias Devreese Journal: Front Pharmacol Date: 2018-01-31 Impact factor: 5.810
Authors: T H T Nguyen; M-S Mouksassi; N Holford; N Al-Huniti; I Freedman; A C Hooker; J John; M O Karlsson; D R Mould; J J Pérez Ruixo; E L Plan; R Savic; J G C van Hasselt; B Weber; C Zhou; E Comets; F Mentré Journal: CPT Pharmacometrics Syst Pharmacol Date: 2017-02-10
Authors: Kristian Vinter Juul; Charlotte Van Herzeele; Pauline De Bruyne; Sandra Goble; Johan Vande Walle; Jens Peter Nørgaard Journal: Eur J Pediatr Date: 2013-05-16 Impact factor: 3.183